STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (ANAB) director Magda Marquet exercises options, sells stock

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio director Magda Marquet reported an option exercise and related share sales. On January 15, 2026, she exercised a fully vested stock option for 11,000 shares of common stock at an exercise price of $26.11 per share, increasing her direct holdings to 20,930 shares. That same day, she sold 9,290 shares of common stock at a weighted average price of $48.1162 per share, in multiple trades between $47.595 and $48.54, and an additional 1,710 shares at a weighted average price of $48.849 per share, in trades between $48.625 and $48.88. After these transactions, she directly owned 9,930 shares of common stock and held additional options to purchase up to 70,104 shares of common stock that vest according to their terms.

Positive

  • None.

Negative

  • None.
Insider Marquet Magda
Role Director
Sold 11,000 shs ($531K)
Type Security Shares Price Value
Exercise Stock Option (right to buy) 11,000 $0.00 --
Exercise Common Stock 11,000 $26.11 $287K
Sale Common Stock 9,290 $48.1162 $447K
Sale Common Stock 1,710 $48.849 $84K
Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 20,930 shares (Direct)
Footnotes (1)
  1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested. In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Marquet Magda
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/15/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/15/2026 M 11,000 A $26.11 20,930 D
Common Stock 01/15/2026 S 9,290 D $48.1162(1) 11,640 D
Common Stock 01/15/2026 S 1,710 D $48.849(2) 9,930 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) $26.11 01/15/2026 M 11,000 (3) 01/17/2031 Common Stock 11,000 $0 0(4) D
Explanation of Responses:
1. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.595 to $48.54 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.625 to $48.88 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. The stock option is fully vested.
4. In addition to the options to purchase shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 70,104 shares of common stock, which options vest according to their terms.
/s/ Eric Loumeau, Attorney-in-Fact 01/16/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did AnaptysBio (ANAB) director Magda Marquet report?

Magda Marquet reported exercising a stock option for 11,000 shares of AnaptysBio common stock at an exercise price of $26.11 per share and selling those shares in market transactions on January 15, 2026.

How many AnaptysBio shares did Magda Marquet sell and at what prices?

On January 15, 2026, she sold 9,290 shares at a weighted average price of $48.1162 per share (in trades from $47.595 to $48.54) and 1,710 shares at a weighted average price of $48.849 per share (in trades from $48.625 to $48.88).

How many AnaptysBio shares does Magda Marquet own after the reported Form 4 trades?

After the reported transactions, Magda Marquet directly beneficially owned 9,930 shares of AnaptysBio common stock.

What options on AnaptysBio stock does Magda Marquet hold following this Form 4?

The exercised stock option for 11,000 shares was fully used and shows 0 remaining from that grant. In addition, she holds options to purchase up to an aggregate of 70,104 shares of AnaptysBio common stock, which vest according to their terms.

Were the AnaptysBio share sales by Magda Marquet single trades or multiple trades?

The reported sale prices are weighted averages. The 9,290 shares were sold in multiple trades between $47.595 and $48.54 per share, and the 1,710 shares were sold in multiple trades between $48.625 and $48.88 per share.

Is Magda Marquet a director or officer of AnaptysBio (ANAB)?

Magda Marquet is reported as a director of AnaptysBio, Inc. and is not listed as an officer or 10% owner in this Form 4.